RxDoctor Payments Data

Loren Mangino, MD

Family Medicine · Forty Fort, PANPI 1851730550

Payments from drug & device makers

$24,580in general payments, 2019–2025

Across 1,723 payments — averaging $14.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Amgen$3K
  • AbbVie$2K
  • Novo Nordisk$2K
  • Boehringer Ingelheim$2K
  • Lilly USA, LLC$1K
  • plus $12K from 53 others

What the payments were for

  • Food & beverage$24,45599%
  • Education$1241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca138$2,789
Amgen174$2,681
AbbVie(2 entities)195$2,402
Novo Nordisk128$1,731
Boehringer Ingelheim108$1,597
Lilly USA, LLC98$1,254
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC135$1,229
Pfizer90$1,138
Bayer43$950
GSK69$910
Takeda Pharmaceuticals U.S.A., Inc.65$898
Astellas Pharma US Inc38$604
Johnson & Johnson51$541
E.r. Squibb & Sons, L.L.C.32$540
Amarin Pharma, Inc.48$436
Radius Health, Inc.25$425
Merck28$409
Lundbeck LLC18$306
Phathom Pharmaceuticals, Inc.23$301
UCB, Inc.19$296
Biohaven Pharmaceuticals, Inc.20$268
Biohaven Pharmaceutical Holding Company Ltd.17$231
Ironwood Pharmaceuticals, Inc13$194
Otsuka America Pharmaceutical, Inc.10$194
Supernus Pharmaceuticals, Inc.14$191
Teva Pharmaceuticals USA, Inc.10$153
Ardelyx, Inc.6$140
Exact Sciences6$127
Esperion Therapeutics, Inc.7$119
Sanofi-aventis U.S. LLC8$118
Shire North American Group Inc10$117
Abbott8$109
Axsome Therapeutics, Inc.5$105
Avanir Pharmaceuticals, Inc.7$99
Dexcom, Inc.5$83
Philips North America LLC3$70
Nabriva Therapeutics, PLC4$59
Cumberland Pharmaceuticals, Inc.3$57
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$52
Novartis3$48
Sunovion Pharmaceuticals Inc.3$47
Sage Therapeutics, LLC2$45
Antares Pharma, Inc.2$42
Xeris Pharmaceuticals, Inc.2$42
Mylan Specialty L.p.3$42
Shield Therapeutics Inc2$40
Idorsia Pharmaceuticals US Inc2$39
Strongbridge US Inc.2$39
Sumitomo Pharma America, Inc.3$38
Eisai Inc.3$38
Vanda Pharmaceuticals Inc.2$35
Paratek Pharmaceuticals, Inc.2$29
Kowa Pharmaceuticals America, Inc.2$27
ANI Pharmaceuticals, Inc.1$23
Almatica Pharma LLC1$22
Verona Pharma, Inc.1$19
Collegium Pharmaceutical, Inc.1$15
Sanofi Pasteur Inc.1$15
QOL Medical, LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,580 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$336,419
Medicare patients
666
Services billed
9,675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban549$333,547
JardianceEmpagliflozin362$280,590
OzempicSemaglutide179$195,459
MounjaroTirzepatide146$164,356
XareltoRivaroxaban162$130,626
OtezlaApremilast17$82,970
TrulicityDulaglutide63$66,527
MyrbetriqMirabegron130$62,856
LinzessLinaclotide51$53,386
TradjentaLinagliptin72$46,021
Breztri AerosphereBudesonide/Glycopyr/Formoterol51$44,622
FarxigaDapagliflozin Propanediol49$42,240
RexultiBrexpiprazole25$35,830
EntrestoSacubitril/Valsartan53$35,711
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$35,581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$1,138$352,919565 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Spiriva Respimat$1,597$352,687487 claims
Lilly USA, LLCMounjaro, Trulicity$1,254$230,883209 claims
Novo NordiskOzempic, Rybelsus$1,731$229,756212 claims
Johnson & JohnsonXarelto$541$130,626162 claims
AstraZenecaBreztri Aerosphere, Farxiga$2,789$86,862100 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$910$86,564185 claims
AmgenOtezla$2,681$82,97017 claims
AbbVieLinzess, Lumigan$2,402$63,08084 claims
Astellas Pharma US IncMyrbetriq$604$62,856130 claims
Otsuka America Pharmaceutical, Inc.Rexulti$194$35,83025 claims
NovartisEntresto$48$35,71153 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Forty Fort

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →